Wall Street Zen Upgrades Lipocine (NASDAQ:LPCN) to “Hold”

Lipocine (NASDAQ:LPCN) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Sunday.

Other equities analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $15.00 price target (up previously from $7.00) on shares of Lipocine in a report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lipocine in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Lipocine Price Performance

Lipocine stock opened at $8.66 on Friday. Lipocine has a one year low of $2.52 and a one year high of $12.37. The company’s fifty day moving average price is $7.55 and its two-hundred day moving average price is $4.59. The company has a market capitalization of $48.06 million, a price-to-earnings ratio of -8.49 and a beta of 0.99.

Institutional Trading of Lipocine

A number of hedge funds have recently bought and sold shares of LPCN. Citadel Advisors LLC acquired a new stake in Lipocine in the 3rd quarter worth $41,000. Jane Street Group LLC acquired a new stake in Lipocine during the fourth quarter worth about $85,000. Geode Capital Management LLC increased its stake in Lipocine by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after acquiring an additional 1,374 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after acquiring an additional 1,300 shares during the period. 9.11% of the stock is owned by institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.